SoftBank revealed new positions in each of these three companies.
AbCellera (Nasdaq: ABCL) today announced that the Company will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference, March 4,...
AbCellera (Nasdaq: ABCL) will announce its full year 2025 financial results on Tuesday, February 24, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)...
AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. ABCL635 is a potential first-in-class...
AbCellera (Nasdaq: ABCL) today announced that it has entered into a settlement and patent license agreement with Bruker Corporation, resolving the patent litigation between the two companies globally....
AbCellera (Nasdaq: ABCL) today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. A live audio webcast of the presentation...
AbCellera (Nasdaq: ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor,...
AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated....
AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: Truist Securities BioPharma Symposium, November 6,...
AbCellera (Nasdaq: ABCL) will announce its third quarter 2025 financial results on Thursday, November 6, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern...